Since at least seven of the panel's 14 members have ties to the peptide industry or clinics promoting them, it's expected they'll advise removing the restrictionseven though FDA scientists in June recommended against doing so, citing insufficient evidence on the peptides' effectiveness and safety
However, discussion does not equal approval
Currently, there are four main treatments propelling this market forward: Ozempic and Wegovy (semaglutide: a GLP-1 agonist, developed by Novo Nordisk) Mounjaro and Zepbound (tirzepatide: a dual agonist targeting both GLP-1 and GIP (Gastric inhibitory polypeptide) receptors, developed by Eli Lilly) These medications are administered subcutaneously with the assistance of injection pens
Request your appointment to get started, or find out more about Dr
The Khavinson question The majority of Epitalon and Pinealon research originates from Professor Vladimir Khavinson research group in Russia
These individuals may benefit from supplementation under medical guidance, with monitoring to ensure appropriate dosing and response to treatment
